You are here

JCAR017

The 20 Hottest Pipeline Drugs to Watch in 2019

BioSpace

Sun, 01/6/19 - 02:09 pm

VX-659 + tezacaftor + ivacaftor

valoctocogene roxaparvovec

3 Biotechs With Potential Blockbusters Near the Finish Line

Motley Fool

Tue, 12/18/18 - 12:48 pm

Vertex Pharmaceuticals

VX-659 + tezacaftor + ivacaftor

ASH18: CAR-T shows up in early CLL test

Biopharma Dive

Sun, 12/2/18 - 10:48 pm

ASCO18: Celgene makes its case as CAR-T rival in lymphoma

Biopharma Dive

Mon, 06/4/18 - 09:34 am

B-cell non-Hodgkin lymphoma

How Celgene Hopes to Cash In on CAR-T

Yahoo/Motley Fool

Sat, 02/17/18 - 10:41 am

As CAR-Ts go from candidates to brands, what's the marketing strategy?

Medical Marketing and Media

Tue, 02/13/18 - 09:01 am

Juno Therapeutics

ASH 2017: CAR-T Wallops Blood Cancer

Motley Fool

Tue, 12/12/17 - 11:16 am

Gilead Sciences

Juno Therapeutics

3 Top Biotech Stocks for 2018

Motley Fool

Mon, 11/13/17 - 09:23 am

Juno Therapeutics

Cara Therapeutics

Juno uses lethal neurotox lessons to guide Goldilocks formula for its next-gen CAR-T

Endpoints

Mon, 11/13/17 - 09:18 am

Juno Therapeutics

3 Biotech Stocks That Soared This Week

Motley Fool

Sat, 11/4/17 - 05:37 pm

Juno Therapeutics

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status

Endpoints

Wed, 11/1/17 - 06:52 pm

Juno Therapeutics

Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important

Motley Fool

Fri, 08/4/17 - 11:37 am

Juno Therapeutics

ASCO17: Juno marks progress with second-gen CAR-T

BioPharma Dive

Tue, 06/6/17 - 12:16 pm

Juno Therapeutics

non-Hodgkin's lymphoma

Juno Therapeutics Could Nearly Double On Data, Multiple Catalysts

Benzinga

Tue, 08/18/15 - 04:16 pm

Juno Therapeutics